Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Brain Nerve ; 75(10): 1121-1127, 2023 Oct.
Artículo en Japonés | MEDLINE | ID: mdl-37849362

RESUMEN

In this paper, we consider the application of "avatar-based communication" to psychiatric care from the perspective of the biopsychosocial model. There are various possible medical applications of avatar-based communication. It has the potential to provide online convenience and liberate humans from the constraints of reality, enable cognitive interventions through body augmentation technology, and even influence biological factors.


Asunto(s)
Comunicación , Modelos Biopsicosociales , Humanos
2.
Allergol Int ; 71(4): 512-519, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35718709

RESUMEN

BACKGROUND: The mechanism of allergic reactions to COVID-19 mRNA vaccines has not been clarified. Polyethylene glycol (PEG) is a potential antigen in the components of vaccines. However, there is little evidence that allergy after COVID-19 mRNA vaccination is related to PEG. Furthermore, the role of polysorbate (PS) as an antigen has also not been clarified. The objective of this study was to investigate whether PEG and PS allergies are reasonable causes of allergic symptoms after vaccination by detecting PEG-specific and PS-specific antibodies. METHODS: Fourteen patients who developed immediate allergic reactions to BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccines and nineteen healthy controls who did not present allergic symptoms were recruited. Serum PEG-specific immunoglobulin E (IgE) and immunoglobulin G (IgG) and PS-specific IgE and IgG were measured by enzyme-linked immunosorbent assay. Skin tests using PEG-2000 and PS-80 were applied to five patients and three controls. RESULTS: Serum levels of PEG-specific IgE and IgG in patients with immediate allergic reactions to the COVID-19 mRNA vaccine were higher than those in the control group. Serum levels of PS-specific IgE in patients with allergy to the vaccine were higher than those in patients of the control group. Intradermal tests using PEG verified the results for PEG-specific IgE and IgG. CONCLUSIONS: The results suggest that PEG is one of the antigens in the allergy to COVID-19 mRNA vaccines. Cross-reactivity between PEG and PS might be crucial for allergy to the vaccines. PEG-specific IgE and IgG may be useful in diagnosing allergy to COVID-19 mRNA vaccines.


Asunto(s)
Vacuna BNT162/efectos adversos , COVID-19 , Hipersensibilidad , COVID-19/diagnóstico , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , Humanos , Hipersensibilidad/diagnóstico , Hipersensibilidad Inmediata , Inmunoglobulina E/sangre , Inmunoglobulina G/sangre , Polietilenglicoles , Polisorbatos , ARN Mensajero , Vacunas Sintéticas , Vacunas de ARNm
3.
Mod Rheumatol ; 29(1): 181-187, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29451047

RESUMEN

OBJECTIVES: Mevalonate kinase deficiency (MKD), a rare autosomal recessive autoinflammatory syndrome, is caused by disease-causing variants of the mevalonate kinase (MVK) gene. A national survey was undertaken to investigate clinical and genetic features of MKD patients in Japan. METHODS: The survey identified ten patients with MKD. Clinical information and laboratory data were collected from medical records and by direct interviews with patients, their families, and their attending physicians. Genetic analysis and measurement of MVK activity and urinary excretion of mevalonic acid were performed. RESULTS: None of the 10 patients harbored MVK disease-causing variants that are common in European patients. However, overall symptoms were in line with previous European reports. Continuous fever was observed in half of the patients. Elevated transaminase was observed in four of the 10 patients, two of whom fulfilled the diagnostic criteria for hemophagocytic lymphohistiocytosis. About half of the patients responded to temporary administration of glucocorticoids and NSAIDs; the others required biologics such as anti-IL-1 drugs. CONCLUSION: This is the first national survey of MKD patients in a non-European country. Although clinical symptoms were similar to those reported in Europe, the incidence of continuous fever and elevated transaminase was higher, probably due to differences in disease-causing variants.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Glucocorticoides/uso terapéutico , Interleucina-1beta/antagonistas & inhibidores , Deficiencia de Mevalonato Quinasa , Fosfotransferasas (Aceptor de Grupo Alcohol)/genética , Anticuerpos Monoclonales Humanizados , Femenino , Pruebas Genéticas/métodos , Humanos , Factores Inmunológicos/uso terapéutico , Lactante , Japón/epidemiología , Masculino , Deficiencia de Mevalonato Quinasa/diagnóstico , Deficiencia de Mevalonato Quinasa/epidemiología , Deficiencia de Mevalonato Quinasa/genética , Ácido Mevalónico/orina , Encuestas y Cuestionarios , Evaluación de Síntomas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...